Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis

Journal of Lipid Research

Volumn 50, Issue 11, 2009, Pages 2193-2202

  Rahman, Shaikh Mizanoor ^a   Qadri, Ishtiaq ^a,c   Janssen, Rachel C ^a   Friedman, Jacob E ^a,b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Diabetes; Inflammation; Insulin resistance; Obesity; Palmitate; Signal transduction

Indexed keywords

4 PHENYLBUTYRIC ACID; ADIPONECTIN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN BETA; CHAPERONE; FENOFIBRATE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 2; PALMITIC ACID; STRESS ACTIVATED PROTEIN KINASE; THAPSIGARGIN; TRIACYLGLYCEROL; TUNICAMYCIN;

ARTICLE; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMP-ACTIVATED PROTEIN KINASES; ANTILIPEMIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FATTY ACIDS; FATTY LIVER; HEPACIVIRUS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; PHENYLBUTYRATES; PHOSPHORYLATION; PROCETOFEN; RECEPTORS, ADIPONECTIN; THAPSIGARGIN; TRIGLYCERIDES; TUNICAMYCIN;

EID: 70350399324     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800633-JLR200     Document Type: Article

References (69)

1. Powell, E. E., W. G. Cooksley, R. Hanson, J. Searle, J. W. Halliday, and L. W. Powell. 1990. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 11: 74-80.
2. Hourigan, L. F., G. A. Macdonald, D. Purdie, V. H. Whitehall, C. Shorthouse, A. Clouston, and E. E. Powell. 1999. Fibrosis in chronic hepatitis C correlates signifi cantly with body mass index and steatosis. Hepatology. 29: 1215-1219.
3. Farrell, G. C., and C. Z. Larter. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43: S99-112.
4. Marion, A. W., A. J. Baker, and A. Dhawan. 2004. Fatty liver disease in children. Arch. Dis. Child. 89: 648-652.
5. Adinolfi, L. E., M. Gambardella, A. Andreana, M. F. Tripodi, R. Utili, and G. Ruggiero. 2001. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specifi c HCV genotype and visceral obesity. Hepatology. 33: 1358-1364.
6. Unger, R. H., and L. Orci. 2002. Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta. 1585: 202-212.
7. Wellen, K. E., and G. S. Hotamisligil. 2005. Infl ammation, stress, and diabetes. J. Clin. Invest. 115: 1111-1119.
8. Tsochatzis, E., G. V. Papatheodoridis, and A. J. Archimandritis. 2006. The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol. 101: 2629-2640.
9. Lin, H. V., J. Y. Kim, A. Pocai, L. Rossetti, L. Shapiro, P. E. Scherer, and D. Accili. 2007. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes. 56: 1969-1976.
10. Kaser, S., A. Moschen, A. Cayon, A. Kaser, J. Crespo, F. Pons-Romero, C. F. Ebenbichler, J. R. Patsch, and H. Tilg. 2005. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 54: 117-121.
11. Jonsson, J. R., A. R. Moschen, I. J. Hickman, M. M. Richardson, S. Kaser, A. D. Clouston, E. E. Powell, and H. Tilg. 2005. Adiponectin and its receptors in patients with chronic hepatitis C. J. Hepatol. 43: 929-936.
12. Liu, C. J., P. J. Chen, Y. M. Jeng, W. L. Huang, W. S. Yang, M. Y. Lai, J. H. Kao, and D. S. Chen. 2005. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J. Hepatol. 43: 235-242.
13. Ma, H., V. Gomez, L. Lu, X. Yang, X. Wu, and S. Y. Xiao. 2009. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 24: 233-237.
14. Vuppalanchi, R., S. Marri, D. Kolwankar, R. V. Considine, and N. Chalasani. 2005. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J. Clin. Gastroenterol. 39: 237-242.
15. Nannipieri, M., F. Cecchetti, M. Anselmino, E. Mancini, G. Marchetti, A. Bonotti, S. Baldi, B. Solito, M. Giannetti, A. Pinchera, et al. 2009. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes. Surg. 19: 467-474.
16. Yamauchi, T., Y. Nio, T. Maki, M. Kobayashi, T. Takazawa, M. Iwabu, M. Okada-Iwabu, S. Kawamoto, N. Kubota, T. Kubota, et al. 2007. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13: 332-339.
17. Tomita, K., Y. Oike, T. Teratani, T. Taguchi, M. Noguchi, T. Suzuki, A. Mizutani, H. Yokoyama, R. Irie, H. Sumimoto, et al. 2008. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology. 48: 458-473.
18. Aygun, C., O. Kocaman, and O. Senturk. 2008. Adiponectin: Is it a novel treatment modality to alleviate liver injury in non-alcoholic fatty liver disease (NAFLD)? Med. Hypotheses. 70: 457-458.
19. Sheikh, M. Y., J. Choi, I. Qadri, J. E. Friedman, and A. J. Sanyal. 2008. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 47: 2127-2133.
20. Capeau, J. 2007. The story of adiponectin and its receptors AdipoR1 and R2: to follow. J. Hepatol. 47: 736-738.
21. Wu, J., and R. J. Kaufman. 2006. From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ. 13: 374-384.
22. Ozcan, U., E. Yilmaz, L. Ozcan, M. Furuhashi, E. Vaillancourt, R. O. Smith, C. Z. Gorgun, and G. S. Hotamisligil. 2006. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 313: 1137-1140.
23. Ozcan, U., Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Gorgun, L. H. Glimcher, and G. S. Hotamisligil. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306: 457-461.
24. Ji, C., R. Mehrian-Shai, C. Chan, Y. H. Hsu, and N. Kaplowitz. 2005. Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol. Clin. Exp. Res. 29: 1496-1503.
25. Day, C. P., and O. F. James. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology. 114: 842-845.
26. Poli, V. 1998. The role of C/EBP isoforms in the control of infl ammatory and native immunity functions. J. Biol. Chem. 273: 29279-29282.
27. Ramji, D. P., and P. Foka. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365: 561-575.
28. Rahman, S. M., J. M. Schroeder-Gloeckler, R. C. Janssen, H. Jiang, I. Qadri, K. N. Maclean, and J. E. Friedman. 2007. CCAAT/enhancing binding protein beta deletion in mice attenuates infl ammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology. 45: 1108-1117.
29. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Effi cient initiation of HCV RNA replication in cell culture. Science. 290: 1972-1974.
30. Qadri, I., M. Iwahashi, G. A. Kullak-Ublick, and F. R. Simon. 2006. Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Mol. Pharmacol. 70: 627-636.
31. Qadri, I., M. Iwahashi, J. M. Capasso, M. W. Hopken, S. Flores, J. Schaack, and F. R. Simon. 2004. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem. J. 378: 919-928.
32. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925.
33. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fi brates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093.
34. Kliewer, S. A., J. M. Lehmann, and T. M. Willson. 1999. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 284: 757-760.
35. Mancini, F. P., A. Lanni, L. Sabatino, M. Moreno, A. Giannino, F. Contaldo, V. Colantuoni, and F. Goglia. 2001. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 491: 154-158.
36. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purifi cation. Can. J. Biochem. Physiol. 37: 911-917.
37. Ji, C. 2008. Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J. Gastroenterol. Hepatol. 23: S16-24.
38. Harding, H. P., Y. Zhang, and D. Ron. 1999. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 397: 271-274.
39. Chen, C., E. E. Dudenhausen, Y. X. Pan, C. Zhong, and M. S. Kilberg. 2004. Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence. J. Biol. Chem. 279: 27948-27956.
40. Schroeder-Gloeckler, J. M., S. M. Rahman, R. C. Janssen, L. Qiao, J. Shao, M. Roper, S. J. Fischer, E. Lowe, D. J. Orlicky, J. L. McManaman, et al. 2007. CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J. Biol. Chem. 282: 15717-15729.
41. Solinas, G., W. Naugler, F. Galimi, M. S. Lee, and M. Karin. 2006. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc. Natl. Acad. Sci. USA. 103: 16454-16459.
42. Vilatoba, M., C. Eckstein, G. Bilbao, C. A. Smyth, S. Jenkins, J. A. Thompson, D. E. Eckhoff, and J. L. Contreras. 2005. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery. 138: 342-351.
43. Tellinghuisen, T. L., M. J. Evans, T. von Hahn, S. You, and C. M. Rice. 2007. Studying hepatitis C virus: making the best of a bad virus. J. Virol. 81: 8853-8867.
44. Bjornsson, E., and P. Angulo. 2007. Hepatitis C and steatosis. Arch. Med. Res. 38: 621-627.
45. Tardif, K. D., G. Waris, and A. Siddiqui. 2005. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 13: 159-163.
46. Ozcan, U., L. Ozcan, E. Yilmaz, K. Duvel, M. Sahin, B. D. Manning, and G. S. Hotamisligil. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell. 29: 541-551.
47. Cheng, Y., S. Dharancy, M. Malapel, and P. Desreumaux. 2005. Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J. Gastroenterol. 11: 7591-7596.
48. Kim, K. H., S. P. Hong, K. Kim, M. J. Park, K. J. Kim, and J. Cheong. 2007. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem. Biophys. Res. Commun. 355: 883-888.
49. Domitrovich, A. M., D. J. Felmlee, and A. Siddiqui. 2005. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J. Biol. Chem. 280: 39802-39808.
50. Gorlach, A., P. Klappa, and T. Kietzmann. 2006. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid. Redox Signal. 8: 1391-1418.
51. Guo, W., S. Wong, W. Xie, T. Lei, and Z. Luo. 2007. Palmitate modulates intracellular signaling, induces endoplasmic reticulum stress, and causes apoptosis in mouse 3T3-L1 and rat primary preadipocytes. Am. J. Physiol. Endocrinol. Metab. 293: E576-586.
52. Mori, K. 2000. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell. 101: 451-454.
53. Harding, H. P., M. Calfon, F. Urano, I. Novoa, and D. Ron. 2002. Transcriptional and translational control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18: 575-599.
54. Borradaile, N. M., X. Han, J. D. Harp, S. E. Gale, D. S. Ory, and J. E. Schaffer. 2006. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 47: 2726-2737
55. Wang, D., Y. Wei, and M. J. Pagliassotti. 2006. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology. 147: 943-951.
56. Bandyopadhyay, G. K., J. G. Yu, J. Ofrecio, and J. M. Olefsky. 2006. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes. 55: 2277-2285.
57. Kraegen, E. W., A. K. Saha, E. Preston, D. Wilks, A. J. Hoy, G. J. Cooney, and N. B. Ruderman. 2006. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am. J. Physiol. Endocrinol. Metab. 290: E471-479.
58. Cao, J., J. L. Li, D. Li, J. F. Tobin, and R. E. Gimeno. 2006. Molecular identification of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de novo triacylglycerol synthesis. Proc. Natl. Acad. Sci. USA. 103: 19695-19700.
59. Folmes, C. D., and G. D. Lopaschuk. 2007. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovasc. Res. 73: 278-287.
60. Memon, R. A., L. H. Tecott, K. Nonogaki, A. Beigneux, A. H. Moser, C. Grunfeld, and K. R. Feingold. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gammaresponsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 141: 4021-4031.
61. Semple, R. K., V. C. Crowley, C. P. Sewter, M. Laudes, C. Christodoulides, R. V. Considine, A. Vidal-Puig, and S. O'Rahilly. 2004. Expression of the thermogenic nuclear hormone receptor coactivator PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects. Int. J. Obes. Relat. Metab. Disord. 28: 176-179.
62. Conjeevaram, H. S., D. E. Kleiner, J. E. Everhart, J. H. Hoofnagle, S. Zacks, N. H. Afdhal, and A. S. Wahed. 2007. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 45: 80-87.
63. Durante-Mangoni, E., R. Zampino, A. Marrone, M. F. Tripodi, L. Rinaldi, L. Restivo, M. Cioffi, G. Ruggiero, and L. E. Adinolfi. 2006. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment. Pharmacol. Ther. 24: 1349-1357.
64. Cua, I. H., J. M. Hui, P. Bandara, J. G. Kench, G. C. Farrell, G. W. McCaughan, and J. George. 2007. Insulin resistance and liver injury in hepatitis C is not associated with virus-specifi c changes in adipocytokines. Hepatology. 46: 66-73.
65. Harano, Y., K. Yasui, T. Toyama, T. Nakajima, H. Mitsuyoshi, M. Mimani, T. Hirasawa, Y. Itoh, and T. Okanoue. 2006. Fenofi brate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 26: 613-620.
66. Kleemann, R., P. P. Gervois, L. Verschuren, B. Staels, H. M. Princen, and T. Kooistra. 2003. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood. 101: 545-551.
67. Gervois, P., R. Kleemann, A. Pilon, F. Percevault, W. Koenig, B. Staels, and T. Kooistra. 2004. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofi brate. J. Biol. Chem. 279: 16154-16160.
68. Bullen, J. W., Jr., S. Bluher, T. Kelesidis, and C. S. Mantzoros. 2007. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am. J. Physiol. Endocrinol. Metab. 292: E1079-1086.
69. Tsuchida, A., T. Yamauchi, Y. Ito, Y. Hada, T. Maki, S. Takekawa, J. Kamon, M. Kobayashi, R. Suzuki, K. Hara, et al. 2004. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem. 279: 30817-30822.